GENFIT evaluates GFT505 on its pre-diabetic patients target population
[FR Version]
Therapeutic potential of GFT505 is demonstrated in the treatment of cardiovascular risk associated with pre-diabetes
New Phase I Clinical Trials with high-dose confirm the excellent tolerance of GFT505
GENFIT assembles 4 international experts for its SAB
GENFIT addressing Investors at Midcap Event in Paris on Sept. 29-30, 2008
GENFIT: New Appointments
GENFIT’s shareholders renew their confidence in the Management Board and the CEO Jean-François Mouney
GENFIT tiendra son Assemblée Générale Annuelle le 28 juin 2008 (in French)
Ajournement de l'Assemblée Générale Annuelle prévue le 10 juin 2008 (in French)
GENFIT secures €7.1 million funding from OSEO as part of the IT-Diab program
GENFIT announces departure of COO Florence Séjourné
Xavier Guille des Buttes appointed Chairman of the Supervisory Board
GENFIT gives an overview of its collaboration with Sanofi-Aventis
GENFIT shows encouraging results in GFT505 first clinical trial of efficacy
GENFIT and PIERRE FABRE Laboratories renew their alliance
